Want to see NZ:PEB full AI Analyst Report?
Top Page
Pacific Edge Limited
(PEB)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.24
▲(0.00% Upside)
Action:N/A
Date:10/05/26
The score is primarily held down by very weak financial performance—sharp FY2026 revenue contraction, negative gross profit, and ongoing cash burn alongside significant equity erosion. Technicals are also soft with weak momentum and the price below key short- to mid-term moving averages, offering only limited signs of stabilization. Valuation is constrained by losses (negative P/E) and no indicated dividend support.
Positive Factors
Cxbladder clinical differentiation
A first-mover position in bladder cancer diagnostics, reinforced by proprietary urine tests and extensive clinical evidence, can support clinician adoption and payer discussions. This creates a durable foundation for commercial expansion if the company continues converting evidence into reimbursed testing volume.
Negative Factors
Sharp revenue and gross-profit deterioration
The latest deterioration in revenue and gross profit suggests that current test volumes, pricing, or cost absorption are not supporting a healthy operating model. Persistent losses reduce reinvestment capacity and make future growth more dependent on a successful commercial recovery rather than internally funded expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Cxbladder clinical differentiation
A first-mover position in bladder cancer diagnostics, reinforced by proprietary urine tests and extensive clinical evidence, can support clinician adoption and payer discussions. This creates a durable foundation for commercial expansion if the company continues converting evidence into reimbursed testing volume.
Read all positive factors
Pacific Edge Limited (PEB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$310.47M
Dividend YieldN/A
Average Volume (3M)538.05K
Price to Earnings (P/E)―
Beta (1Y)-1.10
Revenue Growth-47.36%
EPS Growth-3.79%
CountryNZ
Employees114
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,241,883,400
10 Day Avg. Volume890,009
30 Day Avg. Volume538,053
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)15.42
Price to Sales (P/S)14.29
P/FCF Ratio-5.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.25Price Target Upside3.40% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$19.50M
Pacific Edge Limited Business Overview & Revenue Model
Company Description
Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001, operates as a cancer diagnostics firm. The company's core mission involves the research, development, and commercialization of advanced diagnostic and prognostic tools aimed...
How the Company Makes Money
Pacific Edge makes money primarily by commercialising its Cxbladder urine-based diagnostic tests and generating revenue from providing those tests as a laboratory service. Revenue is typically earned when clinicians, hospitals, or healthcare payer...
Pacific Edge Limited Earnings Call Summary
Earnings Call Date:Nov 25, 2025
(Q2-2026)
| % Change Since: |
Next Earnings Date:Dec 01, 2026
Earnings Call Sentiment Neutral
The earnings call presents a mixed view, with notable strategic achievements and promising future prospects, particularly with the upcoming Contractor Advisory Committee. However, significant challenges remain due to reduced revenue, test volumes, and the impact of Medicare non-coverage, creating financial strains and operational hurdles.Positive Updates
Strategic Positioning and Market Presence
Despite a net loss, Pacific Edge maintains a strong strategic position by achieving significant milestones and maintaining a U.S. market presence to appeal Medicare and commercial tests. The company is in the strongest position to drive Medicare policy change.
Negative Updates
Decline in Operating Revenue
Operating revenue was down to $5.9 million from $10.9 million in the previous half, mainly due to the loss of Medicare coverage.
Read all updates
Q2-2026 Updates
Positive
Negative
Strategic Positioning and Market Presence
Despite a net loss, Pacific Edge maintains a strong strategic position by achieving significant milestones and maintaining a U.S. market presence to appeal Medicare and commercial tests. The company is in the strongest position to drive Medicare policy change.
Read all positive updates
Company Guidance
In the Pacific Edge 1H Financial Results Presentation for Fiscal Year 2026, the company reported a net loss of $19.1 million and operating revenue of $5.9 million, down from $10.9 million in the previous period. Cash reserves were at $22.1 million, partly bolstered by a $20.7 million capital raise in August 2025. The company faced challenges due to a Medicare non-coverage determination, impacting test volumes and revenue, especially in the U.S. However, Pacific Edge achieved a milestone with Triage Plus, securing a price of USD 1,328 per test, up from $760. Sales force efficiency was maintained, with a sales FTE average of 12, down from over 30, reflecting cost management efforts. The company is optimistic about a potential Medicare re-coverage following a Contractor Advisory Committee (CAC) meeting scheduled for February 19, 2026. They are appealing over 2,000 denied tests to Medicare and commercial providers, expecting revenue recognition in the second half of the year. Additionally, Pacific Edge is pursuing international market expansion with IVD products and focusing on product innovation like Triage Plus and Surveillance Plus for long-term growth.Pacific Edge Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.50M | 21.85M | 26.06M | 19.62M | 11.45M |
| Gross Profit | -936.00K | 8.44M | 14.31M | 9.60M | 4.56M |
| EBITDA | -35.23M | -31.76M | ― | -32.80M | -21.80M |
| Net Income | -35.78M | -29.94M | -29.54M | -26.96M | -19.79M |
Balance Sheet | |||||
| Total Assets | 17.60M | 37.03M | 65.45M | 97.12M | 124.03M |
| Cash, Cash Equivalents and Short-Term Investments | 7.78M | 22.57M | 50.26M | 77.79M | 105.41M |
| Total Debt | 1.28M | 2.90M | 4.21M | 1.22M | 1.92M |
| Total Liabilities | 6.94M | 10.95M | 10.83M | 8.71M | 7.43M |
| Stockholders Equity | 10.66M | 26.09M | 54.62M | 88.41M | 116.60M |
Cash Flow | |||||
| Free Cash Flow | -32.07M | -26.01M | -27.12M | -28.48M | -18.68M |
| Operating Cash Flow | -31.94M | -24.74M | -25.75M | -25.57M | -17.55M |
| Investing Cash Flow | 12.95M | 6.70M | 22.19M | 22.47M | -52.13M |
| Financing Cash Flow | 17.48M | -1.64M | -1.11M | -1.28M | 100.66M |
Pacific Edge Limited Technical Analysis
Negative
0.24
Price Trends
0.26
Negative
0.27
Negative
0.23
Positive
Market Momentum
<0.01
Positive
41.90
Neutral
11.43
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:PEB, the sentiment is Negative. The current price of 0.24 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.26, and above the 200-day MA of 0.23, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.90 is Neutral, neither overbought nor oversold. The STOCH value of 11.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NZ:PEB.
Pacific Edge Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $27.05B | 58.10 | 22.84% | 1.63% | 15.59% | 23.94% | |
60 Neutral | $3.92B | 14.35 | 7.99% | 6.57% | 16.36% | 5.52% | |
54 Neutral | $458.30M | 30.91 | 14.07% | 0.67% | 22.44% | 23.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $13.62M | -3.87 | -75.57% | ― | 42.20% | 23.68% | |
42 Neutral | $310.47M | -6.27 | -190.54% | ― | -47.36% | -3.79% |
* Healthcare Sector Average
NZ:PEB
Pacific Edge Limited
0.24
0.04
23.08%
NZ:EBO
EBOS Group Limited
18.50
-9.44
-33.78%
NZ:FPH
Fisher & Paykel Healthcare Corporation Limited
46.57
9.52
25.70%
NZ:TRU
TruScreen Group Ltd.
0.01
>-0.01
-29.41%
NZ:AFT
AFT Pharmaceuticals Ltd.
4.30
1.51
54.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.